Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G
Department of Urology, University of Patras, School of Medicine, Patras, Greece.
J Urol. 2003 Jun;169(6):2253-6. doi: 10.1097/01.ju.0000067541.73285.eb.
We evaluate the effect of tolterodine combined with tamsulosin on quality of life in patients with bladder outlet obstruction and concomitant detrusor instability.
The study included 50 consecutive patients with urodynamically proven mild or moderate bladder outlet obstruction and concomitant detrusor instability. All patients were initially treated with 0.4 mg. tamsulosin orally once a day. A week later the patients were randomly allocated into group 1-25 who continued treatment with tamsulosin only and, group 2-25 who also received 2 mg. tolterodine orally twice daily. Reevaluation with a quality of life questionnaire and urodynamic study was performed after 3 months.
Two patients from group 2 stopped tolterodine while 1 patient from each group stopped tamsulosin because of hypotension. Analysis revealed statistically significant improvement in quality of life scores only in group 2 patients (mean score 525.0 and 628.4 before and after treatment, respectively, 2-sided t test p = 0.0003). A significant difference was noted in both groups after treatment for maximum flow rate and volume at first contraction. Additionally, in group 2, a statistically significant difference was observed for maximum detrusor pressure and maximum unstable contraction pressure after treatment.
Combination treatment with an alpha-blocker (tamsulosin) plus an anticholinergic (tolterodine) improves quality of life in patients with bladder outlet obstruction and concomitant detrusor instability. Interestingly, no acute urinary retention was observed and tolterodine did not affect the quality of urine flow or residual urine volume. The proposed combination appears to be an effective and relatively safe treatment option in patients with bladder outlet obstruction and detrusor instability.
我们评估托特罗定联合坦索罗辛对膀胱出口梗阻合并逼尿肌不稳定患者生活质量的影响。
该研究纳入了50例经尿动力学证实为轻度或中度膀胱出口梗阻且合并逼尿肌不稳定的连续患者。所有患者最初口服0.4mg坦索罗辛,每日1次。1周后,患者被随机分为两组,第1组25例,仅继续接受坦索罗辛治疗;第2组25例,同时还接受2mg托特罗定口服,每日2次。3个月后,使用生活质量问卷和尿动力学研究进行重新评估。
第2组有2例患者停用托特罗定,每组各有1例患者因低血压停用坦索罗辛。分析显示,仅第2组患者的生活质量评分有统计学意义的改善(治疗前后平均评分分别为525.0和628.4,双侧t检验p = 0.0003)。两组治疗后的最大尿流率和首次排尿收缩时的尿量均有显著差异。此外,第2组治疗后的最大逼尿肌压力和最大不稳定收缩压力有统计学意义的差异。
α受体阻滞剂(坦索罗辛)加抗胆碱能药物(托特罗定)联合治疗可改善膀胱出口梗阻合并逼尿肌不稳定患者的生活质量。有趣的是,未观察到急性尿潴留,且托特罗定不影响尿流质量或残余尿量。所提出的联合治疗似乎是膀胱出口梗阻和逼尿肌不稳定患者的一种有效且相对安全的治疗选择。